PHAR Stock Analysis: Buy, Sell, or Hold?
PHAR - Pharming Group N.V. ADS, each representing 10 ordinary shares
$9.75
-0.20 (-2.01%)
▼
5d:
-6.79%
30d:
-12.95%
90d:
-31.87%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When PHAR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PHAR shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PHAR shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$3.27
Based on -14.6% avg growth
INTRINSIC VALUE TODAY
$2.03
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHAR is currently trading at $9.75, which is considered oversold relative to its 30-day fair value range of $10.32 to $11.49. From a valuation perspective, the stock is trading at a discount (Forward PE: 31.8) compared to its historical average (182.6). Remarkably, the market is currently pricing in an annual earnings decline of 44.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PHAR is in a strong downtrend. The price is currently testing key support at $9.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PHAR scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $34.35 (+252.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PHAR is in a strong downtrend. The price is currently testing key support at $9.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PHAR scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $34.35 (+252.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$10.32 -
$11.49
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 252.3% below Wall St target ($34.35)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.32 -
$11.49
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$9.75
Resistance Level
$11.50
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
31.76
Wall Street Target
$34.35
(+252.3%)
Revenue Growth (YoY)
-3.2%
Earnings Growth (YoY)
-62.9%
Profit Margin
2.5%
Valuation Discount vs History
-44.2% cheaper
PE vs Historical
31.8 vs 182.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-44.2%
(market-implied from PE analysis)
1-Year Target
$8.77
(-10%)
2-Year Target
$7.90
(-19%)
3-Year Target
$7.11
(-27%)
3-Yr Target (if PE normalizes)
(PE: 32→183)
$40.87
(+319%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 31.8, Growth: -33.3%)
$7.11
(+-27%)
Base:
(SPY PE: 20.4, Growth: -33.3%)
$4.57
(-53%)
Bear:
(PE: 17.3, Growth: -33.3%)
$3.88
(-60%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (71x PE), but valuation improves significantly next year (32x PE) as earnings recover.
Trailing PE: 71.07 | Current EPS (TTM): $0.14
Bull Case
$21.89
(+125%)
Analyst growth 100.0%, PE expands to 78.2
Base Case
$19.90
(+104%)
Market implied 100.0%, PE stable at 71.1
Bear Case
$6.77
(-31%)
Severe decline -20.0%, PE contracts to 60.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 31.8 to 182.6
Stabilization Target:
$56.06
(+475.0%)
PE Expansion Potential:
+475.0%
Share & Embed Analysis
Last updated: October 03, 2026 12:24 AM ET
Data refreshes hourly during market hours. Next update: 1:24 AM
Data refreshes hourly during market hours. Next update: 1:24 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
